Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease. (2023)
Attributed to:
Precision Medicine in Crohn's Disease and Ulcerative Colitis: Predicting Disease Flare and Disease progression
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.dld.2022.10.002
PubMed Identifier: 36283944
Publication URI: http://europepmc.org/abstract/MED/36283944
Type: Journal Article/Review
Volume: 55
Parent Publication: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Issue: 8
ISSN: 1590-8658